- Conditions
- HIV Infections
- Interventions
- Stavudine, Didanosine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Tarzana, California • Indianapolis, Indiana + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 18,300
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Traumatic Femur Fracture
- Interventions
- Ropivicaine, Epinephrine
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Bacterial Pneumonia
- Interventions
- Ceftaroline fosamil for Injection, Ceftriaxone, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 622 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Peripheral Artery Disease
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban-Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 6,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 105
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 91 more
- Conditions
- Migraine Disorders, Headache Disorders
- Interventions
- SPN-538, Placebo
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia, Ulcers
- Interventions
- HGF plasmid, Placebo
- Genetic
- Lead sponsor
- AnGes USA, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 4
- States / cities
- Pensacola, Florida • Indianapolis, Indiana • Boston, Massachusetts + 1 more
- Conditions
- Primary IgA Nephropathy
- Interventions
- Sefaxersen (RO7434656), Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Glendale, California • Los Angeles, California + 15 more
- Conditions
- Alopecia Areata
- Interventions
- Rezpegaldesleukin, Placebo
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 10
- States / cities
- Northridge, California • Atlanta, Georgia • Gurnee, Illinois + 7 more
- Conditions
- Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Breast Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Oligo-fucoidan, Placebo Administration, Questionnaire Administration
- Procedure · Dietary Supplement · Drug + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- HIV Infections
- Interventions
- Racivir, a non-nucleoside reverse transcriptase inhibitor
- Drug
- Lead sponsor
- Pharmasset
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • The Bronx, New York • Columbia, South Carolina
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Cutaneous Dysplastic Nevus
- Interventions
- Biopsy Procedure, Biospecimen Collection, Placebo Administration, Sulforaphane
- Procedure · Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- BEA 2180 BR, Tiotropium Bromide, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 2,080 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 56
- States / cities
- Jasper, Alabama • Mobile, Alabama • Berkeley, California + 50 more
- Conditions
- HIV Prevention
- Interventions
- 200 mg of DPV + 320 mg LNG, 200 mg of DPV
- Combination Product
- Lead sponsor
- International Partnership for Microbicides, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Pittsburgh, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 2, Hyperglycemia
- Interventions
- Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd, Empagliflozin high dose qd, Empagliflozin low dose bid, Empagliflozin high dose bid
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Manley Hot Springs, Alaska • Glendale, Arizona + 33 more
- Conditions
- Schizophrenia, Impaired Cognition
- Interventions
- EVP-6124, Placebo
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 753 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Anaheim, California • Bellflower, California + 35 more
- Conditions
- Overactive Bladder
- Interventions
- Dried Cranberry, Placebo Oral Capsule
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Minority Stress, Psychological Stress, Anxiety
- Interventions
- Ashwagandha Root Extract, Placebo Capsule
- Dietary Supplement · Other
- Lead sponsor
- SF Research Institute, Inc.
- Network
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Tocilizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 19
- States / cities
- Huntington Beach, California • Aventura, Florida • Miami, Florida + 16 more
- Conditions
- Chronic Refractory Cough (CRC) With Non-atopic Asthma, CRC With Atopic Asthma, Unexplained Chronic Cough, CRC With Chronic Obstructive Pulmonary Disease, CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
- Interventions
- GDC-6599, GDC-6599-matching placebo, Mannitol
- Drug · Other · Diagnostic Test
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Northridge, California • Coral Gables, Florida + 5 more
- Conditions
- Parkinson's Disease, Overactive Bladder
- Interventions
- Oxybutynin and darifenacin
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- LAF237 = vildagliptin
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Critical Limb Ischemia
- Interventions
- HGF Plasmid (AMG0001), Matching Placebo
- Biological
- Lead sponsor
- AnGes USA, Inc.
- Industry
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 28
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 23 more
- Conditions
- Healthy
- Interventions
- PRA052, Placebo
- Drug · Other
- Lead sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Hantavirus Pulmonary Syndrome
- Interventions
- Ribavirin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama